Vaspin in type 2 diabetes in relation to atherosclerosis
Tóm tắt
Vaspin is a novel adipocytokine with insulin-sensitizing effects. However, it is not known whether a correlation exists between human vaspin serum levels and markers of insulin sensitivity and glucose or lipid metabolism. To determine whether there is an association between serum vaspin levels (a novel adipocytokine with insulin-sensitizing effects), type 2 diabetes mellitus (T2D) and atherosclerosis. The study included 40 patients with T2D divided into 20 without hypertension (group 1), 20 with hypertension (group 2) and 15 age-matched and sex-matched healthy control participants (group 3). The serum vaspin level was determined by enzyme-linked immunosorbent assay. Its level was compared between both diabetic patients and controls, and between diabetic patients without hypertension and those with hypertension. All participants were subjected to an imaging procedure in the form of carotid Doppler to measure the intima — media thickness as an early marker of atherosclerosis. The serum vaspin level was significantly higher in diabetic patients compared with control participants. There was significant increase in the left carotid intima–media thickness in diabetic patients with hypertension and without hypertension compared with control participants. There was a significant positive correlation between the serum vaspin level and the BMI in diabetic patients with hypertension, a significant negative correlation between the serum vaspin level and the duration of diabetes and a significant negative correlation between the serum vaspin level and HDL in diabetic patients without hypertension. There was a significantly high level of serum vaspin in T2D patients. Serum vaspin was shown to be significantly lower in T2D patients with a longer duration of illness. An increased carotid intima–media thickness in diabetic patients was not related to the vaspin level, denoting an underlying combining factor for atherosclerosis in diabetic patients other than vaspin.
Tài liệu tham khảo
Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010; 87:4–14.
Stas SN, El Atat FA, Sowers JR. Pathogenesis of hypertension in diabetes. Rev Endocr Metab Disord 2004; 5:221–225.
Maiti R, Agrawal NK. Atherosclerosis in diabetes mellitus: role of inflammation. Indian J Med Sci 2007; 61:292–306.
Ernst MC, Sinal CJ. Chemerin: at the crossroads of inflammation and obesity. Trends Endocrinol Metab 2010; 21:660–667.
Lago F, Dieguez C, Gómez-Reino J, Gualillo O. The emerging role of adipokines as mediators of inflammation and immune responses. Cytokine Growth Factor Rev 2007; 18:313–325.
Kawano K, Hirashima T, Mori S, Saitoh Y, Kurosumi M, Natori T. Spontaneous long-term hyperglycemic rat with diabetic complications. Otsuka Long-Evans Tokushima Fatty (OLETF) strain. Diabetes 1992; 41:1422–1428.
American Diabetes Association. Report of the Expert Committee on the diagnosis and classification of diabetes mellitus. Diabetes care 2003; 26:5–20.
Friedwald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 1972; 18:499–502.
Inoue J, Wada J, Teshigawara S, Hida K, Nakatsuka A, Takatori Y, et al. The serum vaspin levels are reduced in Japanese chronic hemodialysis patients. BMC Nephrol 2012; 313:163.
Ye Y, Hou XH, Pan XP, Lu JX, Jia WP. Serum vaspin level in relation to postprandial plasma glucose concentration in subjects with diabetes. Chin Med J (Engl) 2009; 122:2530–2533.
El-Mesallamy HO, Kassem DH, El-Demerdash E, Amin AI. Vaspin and visfatin/Nampt are interesting interrelated adipokines playing a role in the pathogenesis of type 2 diabetes mellitus. Metabolism 2011; 60:63–70.
Domaa AM, El-Bagori NN, El- Sayd MM. The clinical significance of vaspin and chemerin in diabetic obese Libyan patients. Curr Sci Int 2012; 2:1–5.
Youn BS, Kloting N, Kratzsch J, Lee N, Park JW, Song ES, et al. Serum vaspin concentrations in human obesity and type 2 diabetes. Diabetes 2008; 57:372–377.
Seeger J, Ziegelmeier M, Bachmann A, Lossner U, Kratzsch J, Bluher M, et al. Serum levels of the adipokine vaspin in relation to metabolic and renal parameters. J Clin Endocrinol Metab 2008; 93:247–251.
Gulcelik NE, Karakaya J, Gedik A, Usman A, Gurlek A. Serum vaspin levels in type 2 diabetic women in relation to microvascular complications. Eur J Endocrinol 2009; 160:65–70.
Klöting N, Berndt J, Kralisch S, Kovacs P, Fasshauer M, Schon MR,et al. Vaspin gene expression in human adipose tissue: association with obesity and type 2 diabetes. Biochem Biophys Res Commun 2006; 339:430–436.
Feng RN, Wang C, Sun CH, Guo FG, Zhao C, Li Y. Vaspin in newly and previously diagnosed Chinese type 2 diabetic females: a case–control study. Asian Biomed 2011; 5:525–529.
Hodis HN, Mack WJ, LaBree L, Selzer RH, Liu CR, Liu CH, et al. Reduction in carotid arterial wall thickness using lovastatin and dietary therapy: a randomized controlled clinical trial. Ann Intern Med 1996; 124:548–556.
O’Leary DH, Polak JF, Kronmal RA, Savage PJ, Borhani NO, Kittner SJ, et al. Thickening of the carotid wall: a marker for atherosclerosis in the elderly?. Stroke 1996; 27:224–231.
Li Z, Ma C, Li L, Pan X, Chen L. Vaspin serum concentration in patients with type 2 diabetes and carotid plaque. J Int Med Res 2012; 40:1670–1676.
Kadoglou NP, Gkontopoulos A, Kapelouzou A, Fotiadis G, Theofilogiannakos EK, Kottas G, et al. Serum levels of vaspin and visfatin in patients with coronary artery disease — Kozani study. Clin Chim Acta 2011; 412:48–52.
Kobat MA, Celik A, Balin M, Altas Y, Baydas A, Bulut M, et al. The investigation of serum vaspin level in atherosclerotic coronary artery disease. J Clin Med Res 2012; 4:110–113.